The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by Goldman Sachs on January 28, 2025. The analyst firm set a price target for $40.00 expecting DNLI to rise to within 12 months (a possible 73.99% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by Goldman Sachs, and Denali Therapeutics maintained their buy rating.

The last upgrade for Denali Therapeutics Inc happened on December 16, 2024 when Stifel raised their price target to $37. Stifel previously had a hold for Denali Therapeutics Inc.

There is no last downgrade for Denali Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on January 28, 2025 so you should expect the next rating to be made available sometime around January 28, 2026.

While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a maintained with a price target of $45.00 to $40.00. The current price Denali Therapeutics (DNLI) is trading at is $22.99, which is out of the analyst’s predicted range.